Amgen Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers the results of Amgen Inc.'s Annual Meeting of Stockholders held on May 19, 2026. The filing details the voting outcomes for director elections, executive compensation, auditor ratification, and a stockholder proposal.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
The following matters were submitted to a vote of security holders:
- Election of Directors: All 12 nominees were elected to one-year terms expiring at the 2027 annual meeting. While all were elected, several directors received significant "Against" votes, ranging from approximately 3 million to 21 million votes.
- Executive Compensation: The advisory vote to approve executive compensation was approved with 399,315,381 votes in favor versus 11,987,682 against.
- Auditor Ratification: Ernst & Young LLP was ratified as the independent registered public accountants for the fiscal year ending December 31, 2026.
- Stockholder Proposal: A proposal to require an independent board chairman was not approved, receiving 72,902,413 votes in favor and 338,465,655 votes against.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific reasons for the elevated "Against" votes for certain director nominees (e.g., Robert A. Bradway and Greg C. Garland received over 20 million "Against" votes).
- Confirm the composition of the Board of Directors following the election of the 12 nominees.
- Note the strong rejection of the stockholder proposal for an independent board chairman, indicating current shareholder support for the existing leadership structure.
- Review the full proxy statement for detailed context on the executive compensation package that was approved.